The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1478
September 28, 2015
View Complete Issue         Table of Contents 2019 
Racemic Amphetamine Sulfate (Evekeo) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Racemic Amphetamine Sulfate (Evekeo) for ADHD
September 28, 2015 (Issue: 1478)
The FDA has approved racemic amphetamine sulfate (Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of narcolepsy in patients ≥6 years old and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Racemic Amphetamine Sulfate (Evekeo) for ADHD
Article code: 1478c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.